Double-blind study of naproxen vs placebo in the treatment of acute migraine attacks.
Naproxen was compared with placebo in a double-blind, crossover trial in classic and common migraine. The trial was terminated at a fixed date; 37 patients had entered, 5 of whom were excluded. Naproxen was given as 750 mg at the first symptom of the attack, a total of 1250 mg per 24 h was allowed. Patients were followed for six attacks or three months in each phase, whichever came first. The severity of the headache was significantly less with naproxen in the first 2 h of the attack (p = 0.047), whereas there was no difference when the whole attack was considered. Significantly more patients preferred naproxen (p = 0.042). Side effects occurred in five patients, causing withdrawal of one patient while on naproxen.
Andersson
P G
PG
Department of Neuromedicine, Hjørring Sygehus, Denmark.
Hinge
H H
HH
Johansen
O
O
Andersen
C U
CU
Lademann
A
A
Gøtzsche
P C
PC
D000208:Acute Disease; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D006801:Humans; D008881:Migraine Disorders / Q000188:drug therapy* / Q000503:physiopathology; D009288:Naproxen / Q000009:adverse effects / Q000627:therapeutic use*; D010919:Placebos; D013272:Stomach Diseases / Q000139:chemically induced
D010919:Placebos; D009288:Naproxen